SCHEMBL28944494

SCHEMBL28944494

CCOC(=O)c1ccc(C(F)(F)F)nc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.48
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46
MAPT P10636 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HSP90AA1 P07900 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
TSHR P16473 3/20 0.46
NPSR1 Q6W5P4 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP1A2 P05177 1/20 0.42
IDO1 P14902 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29827383 1.00 KDM4E (0.48) KDM4ECA12CA1CA2CA7
SCHEMBL31697314 0.86 KDM4E (0.50) KDM4ECA12CA1CA2CA7
SCHEMBL1498542 0.86 KDM4E (0.50) KDM4ECA12CA1CA2CA7
SCHEMBL24834467 0.85 KDM4E (0.48) KDM4ECA12CA1CA2CA7
SCHEMBL4192553 0.85 KDM4E (0.58) KDM4ECA12CA1CA2CA7
SCHEMBL16389719 0.84 KDM4E (0.47) KDM4ECA12CA1CA2CA7
SCHEMBL9588785 0.84 KDM4E (0.47) KDM4ECA12CA1CA2CA7
SCHEMBL6216482 0.84 KDM4E (0.47) KDM4ECA12CA1CA2CA7
SCHEMBL1375048 0.84 KDM4E (0.53) KDM4EMAPTMEN1KMT2ATSHR
SCHEMBL9264129 0.83 TUBB4A (0.54) KDM4ECA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4698517-A1 <SUP2/>? <SUB2/>?4?NOVEL COMPOUNDS AS ?? <NS1:SUB>7</NS1:SUB>?INHIBITORS Evotec International GmbH (DE) 2026-02-25 EP disclosed
US-20260042760-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY ACONCAGUA BIO INC (US) 2026-02-12 US disclosed
US-12486269-B2 Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity ACONCAGUA BIO, INC. (US) 2025-12-02 US disclosed
US-20250257067-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY ACONCAGUA BIO, INC. 2025-08-14 US disclosed
WO-2024218058-A1 NOVEL COMPOUNDS AS α4β7 INHIBITORS EVOTEC INTERNATIONAL GMBH (DE) 2024-10-24 WO disclosed
CN-114599644-A Nicotinamide compound and herbicide composition containing the same 韩国化学研究院 2022-06-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486269-B2 Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity IAPP, GIPR, SCTR KDM4E 4867/4885CA12 1768/4885CA1 2089/4885
US-20260042760-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY NPY1R, CALCRL, SCTR KDM4E 4872/4885CA12 1055/4885CA1 920/4885
US-20250257067-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY IAPP, GIPR, SCTR KDM4E 4867/4885CA12 1768/4885CA1 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.